XPH Valuation

State Street SPDR S&P Pharmaceuticals ETF (XPH) is now in the Fair zone, suggesting that its current forward PS ratio of NaN is considered Fairly compared with the five-year average of --. The fair price of State Street SPDR S&P Pharmaceuticals ETF (XPH) is between -- to -- according to relative valuation method.

XPH's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of State Street SPDR S&P Pharmaceuticals ETF (XPH) is between -- to -- according to relative valuation method.

The average P/S ratio for XPH's competitors is 0.00, providing a benchmark for relative valuation. State Street SPDR S&P Pharmaceuticals ETF Corp (XPH) exhibits a P/S ratio of --, which is 0% above the industry average. Given its robust revenue growth of 0%, this premium appears unsustainable.

As of Mar 04 2026, State Street SPDR S&P Pharmaceuticals ETF (XPH) has a P/B ratio of NaN. This indicates that the market values XPH at NaN times its book value.

As of Mar 04 2026, State Street SPDR S&P Pharmaceuticals ETF (XPH) has a FCF Yield of NaN%. This means that for every dollar of State Street SPDR S&P Pharmaceuticals ETF's market capitalization, the company generates NaN cents in free cash flow.

As of Mar 04 2026, State Street SPDR S&P Pharmaceuticals ETF (XPH) has a Forward P/E ratio of NaN. This means the market is willing to pay $NaN for every dollar of State Street SPDR S&P Pharmaceuticals ETF's expected earnings over the next 12 months.

As of Mar 04 2026, State Street SPDR S&P Pharmaceuticals ETF (XPH) has a Forward P/S ratio of NaN. This means the market is valuing XPH at $NaN for every dollar of expected revenue over the next 12 months.